12 Greenway Plaza
13 articles with Memgen
11/19/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Memgen, Inc., a clinical-stage biotechnology company developing potentially life-saving cancer immunotherapies, announced that Kevin M. Coveney, CPA, has been appointed Chief Financial Officer.
Memgen, Inc. announced that the U.S. Food and Drug Administration has accepted its investigational new drug application for MEM-288, the company’s wholly-owned cancer immunotherapy candidate for the treatment of multiple solid tumors.
This week, the U.S. Food and Drug Administration accepted Investigational New Drug Applications for multiple companies, clearing the way for clinical development.
ImmunoCellular Therapeutics And Memgen Announce Letter Of Intent For Potential Joint Immuno-Oncology Collaboration
Memgen Announces Preclinical Results For Its ISF35 Cancer Immunotherapy With Checkpoint Inhibitors In Metastatic Melanoma
Memgen Announces Upcoming Presentation for ISF35 in Chronic Lymphocytic Leukemia at 2011 Memgen Annual Meeting
Memgen Announces Clinical and Preclinical Results for ISF35 in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
Memgen's Clinical Trial Results of ISF35 for Chronic Lymphocytic Leukemia Selected for Presentation at American Society of Hematology 2009 Annual Meeting
Memgen's Clinical Results on Leukemia Selected for Presentation at 2008 American Society of Hematology Annual Meeting